Experimental drug targets tough blood cancers in early safety trial

NCT ID NCT07101328

Summary

This early-stage trial is testing a new drug called LY4152199 in people with B-cell lymphomas that have returned or didn't respond to previous treatments. The main goals are to find a safe dose and see if the drug shows any signs of helping control the cancer. The study will enroll 215 adults who have already tried at least two other treatments for their lymphoma.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AIDPORT Sp. z o.o.

    Skorzewo, 60-185, Poland

  • AP-HP Hopital Saint-Louis

    Paris, 75010, France

  • Aarhus University Hospital

    Aarhus, N 8200, Denmark

  • Asan Medical Center

    Seoul, 05505, South Korea

  • BC Cancer - Vancouver

    Vancouver, V5Z 1L3, Canada

  • Bayside Health (Alfred)

    Melbourne, VIC, 3004, Australia

  • CHU de Lille - Hopital Claude Huriez

    Lille, 59037, France

  • Cancer Institute Hospital of JFCR

    Tokyo, 135-8550, Japan

  • Center for Cancer and Organ Diseases - Rigshospitalet

    Copenhagen, 2100, Denmark

  • Charite Universitaetsmedizin Berlin

    Berlin, 10117, Germany

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    Bologna, 40138, Italy

  • Institut Catala d'Oncologia - L'Hospitalet

    Barcelona, 08908, Spain

  • Intermountain Healthcare

    Salt Lake City, Utah, 84111, United States

  • Istituto Clinico Humanitas

    Rozzano, 20089, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Napoli, 80131, Italy

  • LMU Klinikum Muenchen-Campus Grosshadern

    München, 80336, Germany

  • Lady Davis Institute for Medical Research Jewish General Hospital

    Montreal, H3T 1E2, Canada

  • Leeds Teaching Hospitals NHS Trust

    Leeds, LS9 7TF, United Kingdom

  • Linear Clinical Research

    Nedlands, 6009, Australia

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic - Rochester

    Rochester, Minnesota, 55905, United States

  • National Cancer Center Hospital East

    Chiba, 277-8577, Japan

  • New York University (NYU) Clinical Cancer Center

    New York, New York, 10016, United States

  • Okayama University Hospital

    Okayama, 700-8558,, Japan

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, OX3 9DU, United Kingdom

  • Pratia MCM Krakow

    Krakow, 30-727, Poland

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Swedish Cancer Institute (SCI)

    Seattle, Washington, 98104, United States

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois, 60637, United States

  • Universitaetsklinikum Muenster

    Münster, 48149, Germany

  • University Health Network (UHN) - Princess Margaret Cancer Centre

    Toronto, M5G 1Z5, Canada

  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus

    Aurora, Colorado, 80045-2559, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Southwestern

    Dallas, Texas, 75244, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

  • Yale University School of Medicine - Yale Cancer Center

    New Haven, Connecticut, 06520-8028, United States

Conditions

Explore the condition pages connected to this study.